Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals
PET Clin. 2024 Apr 23:S1556-8598(24)00018-X. doi: 10.1016/j.cpet.2024.03.003. Online ahead of print.ABSTRACTNovel prostate-specific membrane antigen (PSMA) ligands labeled with α-emitting radionuclides are sparking a growing interest in prostate cancer treatment. These targeted alpha therapies (TATs) have attractive physical properties that deem them effective in progressive metastatic castrate-resistant prostate cancer (mCRPC). Among the PSMA TAT radiopharmaceuticals, [225Ac]Ac-PSMA has been used extensively on a compassionate basis and is currently undergoing phase I trials. Notably, TAT has the potential to improve qua...
Source: Clinical Prostate Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Honest Ndlovu Kgomotso M G Mokoala Ismaheel Lawal Louise Emmett Mike M Sathekge Source Type: research
Reducing False-Positives Due to Urinary Stagnation in the Prostatic Urethra on 18F-DCFPyL PSMA PET/CT With MRI
CONCLUSIONS: Stagnated urine within the prostatic urethra is a potential confounding factor on PSMA PET scans. Integrating PET imaging with T2W MRI can mitigate false-positive calls, especially as PSMA PET/CT continues to gain traction in diagnosing localized prostate cancer.PMID:38651785 | DOI:10.1097/RLU.0000000000005220 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 23, 2024 Category: Cancer & Oncology Authors: David G Gelikman Esther Mena Liza Lindenberg William S Azar Nityam Rathi Enis C Yilmaz Stephanie A Harmon Kyle C Schuppe Jessica Y Hsueh Hannah Huth Bradford J Wood Sandeep Gurram Peter L Choyke Peter A Pinto Baris Turkbey Source Type: research
Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up
CONCLUSION: Reirradiation with EBRT for locally recurrent PCa after primary curative radiation therapy is clinically feasible and demonstrated a favorable outcome with acceptable toxicity in this prospective study with long-term follow-up.PMID:38652872 | DOI:10.1200/JCO.23.01391 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Christian Ekanger Svein Inge Helle Lars Reis æter Liv Bolstad Hysing Rune Kv åle Alfred Honor é Karsten Gravdal Sara Pilskog Olav Dahl Source Type: research
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations
CONCLUSIONS: Treatment patterns identified in this study were similar to those among patients with mCRPC regardless of tumor HRR mutation status in the literature.PMID:38653037 | DOI:10.1016/j.clgc.2024.102080 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Priyanka J Bobbili Jasmina Ivanova David B Solit Niharika B Mettu Shannon J McCall Mallika Dhawan Maral DerSarkissian Bhakti Arondekar Jane Chang Alexander Niyazov Jocelyn Lee Risha Huq Michelle Green Michelle Turski Phu Lam Aruna Muthukumar Tracy Guo Man Source Type: research
Reducing False-Positives Due to Urinary Stagnation in the Prostatic Urethra on 18F-DCFPyL PSMA PET/CT With MRI
CONCLUSIONS: Stagnated urine within the prostatic urethra is a potential confounding factor on PSMA PET scans. Integrating PET imaging with T2W MRI can mitigate false-positive calls, especially as PSMA PET/CT continues to gain traction in diagnosing localized prostate cancer.PMID:38651785 | DOI:10.1097/RLU.0000000000005220 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 23, 2024 Category: Cancer & Oncology Authors: David G Gelikman Esther Mena Liza Lindenberg William S Azar Nityam Rathi Enis C Yilmaz Stephanie A Harmon Kyle C Schuppe Jessica Y Hsueh Hannah Huth Bradford J Wood Sandeep Gurram Peter L Choyke Peter A Pinto Baris Turkbey Source Type: research
Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up
CONCLUSION: Reirradiation with EBRT for locally recurrent PCa after primary curative radiation therapy is clinically feasible and demonstrated a favorable outcome with acceptable toxicity in this prospective study with long-term follow-up.PMID:38652872 | DOI:10.1200/JCO.23.01391 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Christian Ekanger Svein Inge Helle Lars Reis æter Liv Bolstad Hysing Rune Kv åle Alfred Honor é Karsten Gravdal Sara Pilskog Olav Dahl Source Type: research
Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer
CONCLUSION: Radiographic progression at the point of CRPC diagnosis independently predicts a shorter OS post-CRPC in patients with mHSPC. Therefore, assessing radiographic changes at the time of CRPC diagnosis could be instrumental in managing CRPC in patients with mHSPC.PMID:38643665 | DOI:10.1016/j.clgc.2024.102075 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 21, 2024 Category: Cancer & Oncology Authors: Kojiro Tashiro Shoji Kimura Shunsuke Tsuzuki Fumihiko Urabe Wataru Fukuokaya Keiichiro Mori Koichi Aikawa Masaya Murakami Hiroshi Sasaki Kenta Miki Jun Miki Tatsuya Shimomura Hiroki Yamada Kenichi Hata Hideomi Nishikawa Hirokazu Abe Ken Watanabe Takahiro Source Type: research
Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years
PET Clin. 2024 Apr 20:S1556-8598(24)00019-1. doi: 10.1016/j.cpet.2024.03.004. Online ahead of print.ABSTRACTEach tumor has its own distinctive molecular identity. Treatment, therefore, should be tailored to this unique cancer phenotype. Theragnostics uses the same compound for targeted imaging and treatment, radiolabeled to an appropriate radionuclide, respectively. Gastrin-releasing peptide receptors (GRPRs) are overexpressed in prostate cancer, and radiolabeled GRPR antagonists have shown high diagnostic performance at staging and biochemical recurrence. Several GRPR-targeting theragnostic compounds have been developed p...
Source: Clinical Prostate Cancer - April 21, 2024 Category: Cancer & Oncology Authors: Simone Dalm Heying Duan Andrei Iagaru Source Type: research
A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia
Asia Pac J Clin Oncol. 2024 Apr 19. doi: 10.1111/ajco.14054. Online ahead of print.ABSTRACTStudies of patients with castrate-resistant prostate cancer at high risk of developing overt metastases but with no current evidence of evaluable disease on computed tomography or bone scan non-metastatic castrate-resistant prostrate cancer have demonstrated increased metastasis-free survival and overall survival following treatment with the next-generation oral anti-androgen apalutamide (in addition to therapies that aim to lower testosterone to castrate levels) or luteinizing hormone-releasing hormone antagonist or surgical castrat...
Source: Clinical Prostate Cancer - April 19, 2024 Category: Cancer & Oncology Authors: Gavin Marx Simon Chowdhury Laurence Krieger Elizabeth Hovey Jeremy Shapiro Ben Tran Thean Hsiang Tan Siobhan Ng Henry H Woo Source Type: research
A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia
Asia Pac J Clin Oncol. 2024 Apr 19. doi: 10.1111/ajco.14054. Online ahead of print.ABSTRACTStudies of patients with castrate-resistant prostate cancer at high risk of developing overt metastases but with no current evidence of evaluable disease on computed tomography or bone scan non-metastatic castrate-resistant prostrate cancer have demonstrated increased metastasis-free survival and overall survival following treatment with the next-generation oral anti-androgen apalutamide (in addition to therapies that aim to lower testosterone to castrate levels) or luteinizing hormone-releasing hormone antagonist or surgical castrat...
Source: Clinical Prostate Cancer - April 19, 2024 Category: Cancer & Oncology Authors: Gavin Marx Simon Chowdhury Laurence Krieger Elizabeth Hovey Jeremy Shapiro Ben Tran Thean Hsiang Tan Siobhan Ng Henry H Woo Source Type: research
Management of advanced prostate cancer in the Asia-Pacific region: Summary of the Asia-Pacific Advanced Prostate Cancer Consensus Conference 2023
CONCLUSION: The use of next-generation imaging, genetic testing, and new treatment combinations is increasing the complexity and duration of prostate cancer management. Familiarity with new diagnostic and treatment options is growing in the APAC region. Insights highlight the continued importance of a multidisciplinary approach that includes nuclear medicine, genetic counseling, and quality-of-life expertise. The APAC APCCC meeting provides an important opportunity to share practice and identify APAC-specific issues and considerations in areas of low evidence where clinical experience is growing.PMID:38628049 | DOI:10.1111...
Source: Clinical Prostate Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Edmund Chiong Declan G Murphy Nicholas Buchan Kenneth Chen Sarah S Chen Melvin L K Chua Agus Rizal Hamid Ravindran Kanesvaran Makarand Khochikar Jason Letran Bannakij Lojanapiwat Indranil Mallik Chee Fai Ng Teng Aik Ong Darren M C Poon Yeong-Shiau Pu Marn Source Type: research
A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer
CONCLUSION: The safety and efficacy of moderately hypofractionated IMRT with prostate-based image-guidance was confirmed among Japanese patients with prostate cancer.PMID:38630382 | DOI:10.1007/s10147-024-02517-z (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Katsumasa Nakamura Keiji Nihei Yoshihiro Saito Naoto Shikama Shin-Ei Noda Ryusuke Hara Toshiyuki Imagumbai Takashi Mizowaki Takeshi Akiba Etsuo Kunieda Masanori Someya Saiji Ohga Jiro Kawamori Takuyo Kozuka Yosuke Ota Koji Inaba Takeshi Kodaira Yoshiyuki Source Type: research
Management of advanced prostate cancer in the Asia-Pacific region: Summary of the Asia-Pacific Advanced Prostate Cancer Consensus Conference 2023
CONCLUSION: The use of next-generation imaging, genetic testing, and new treatment combinations is increasing the complexity and duration of prostate cancer management. Familiarity with new diagnostic and treatment options is growing in the APAC region. Insights highlight the continued importance of a multidisciplinary approach that includes nuclear medicine, genetic counseling, and quality-of-life expertise. The APAC APCCC meeting provides an important opportunity to share practice and identify APAC-specific issues and considerations in areas of low evidence where clinical experience is growing.PMID:38628049 | DOI:10.1111...
Source: Clinical Prostate Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Edmund Chiong Declan G Murphy Nicholas Buchan Kenneth Chen Sarah S Chen Melvin L K Chua Agus Rizal Hamid Ravindran Kanesvaran Makarand Khochikar Jason Letran Bannakij Lojanapiwat Indranil Mallik Chee Fai Ng Teng Aik Ong Darren M C Poon Yeong-Shiau Pu Marn Source Type: research
A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer
CONCLUSION: The safety and efficacy of moderately hypofractionated IMRT with prostate-based image-guidance was confirmed among Japanese patients with prostate cancer.PMID:38630382 | DOI:10.1007/s10147-024-02517-z (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Katsumasa Nakamura Keiji Nihei Yoshihiro Saito Naoto Shikama Shin-Ei Noda Ryusuke Hara Toshiyuki Imagumbai Takashi Mizowaki Takeshi Akiba Etsuo Kunieda Masanori Someya Saiji Ohga Jiro Kawamori Takuyo Kozuka Yosuke Ota Koji Inaba Takeshi Kodaira Yoshiyuki Source Type: research
The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression
J Clin Invest. 2024 Apr 16:e170809. doi: 10.1172/JCI170809. Online ahead of print.ABSTRACTJust as the androgen receptor (AR), the estrogen receptor α (ERα) is expressed in the prostate and is thought to influence prostate cancer (PCa) biology. Yet, the incomplete understanding of ERα functions in PCa hinders our ability to fully comprehend its clinical relevance and restricts the repurposing of estrogen-targeted therapies for the treatment of this disease. Using two human PCa tissue microarray cohorts, we first demonstrated that nuclear ERα expression was heterogeneous among patients, being only detected in half of tum...
Source: Clinical Prostate Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Camille Lafront Lucas Germain Gabriel H Campolina-Silva Cindy Weidmann Line Berthiaume H élène Hovington Herv é Brisson Cynthia Jobin Lilianne Fr égeau-Proulx Raul Cotau Kevin Gonthier Aur élie Lacouture Patrick Caron Claire M énard Chantal Atallah Source Type: research
